Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Status of vaccine research and development for Clostridium difficile.

Riley TV, Lyras D, Douce GR.

Vaccine. 2019 Mar 19. pii: S0264-410X(19)30259-2. doi: 10.1016/j.vaccine.2019.02.052. [Epub ahead of print]

PMID:
30902484
2.

A Role for Tetracycline Selection in Recent Evolution of Agriculture-Associated Clostridium difficile PCR Ribotype 078.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Marwick CA, Coia J, Brown D, Buchanan S, Ijaz UZ, Goswami C, Douce G, Fawley WN, Wilcox MH, Peto TEA, Walker AS, Crook DW.

MBio. 2019 Mar 12;10(2). pii: e02790-18. doi: 10.1128/mBio.02790-18.

3.

Author Correction: Host-associated niche metabolism controls enteric infection through fine-tuning the regulation of type 3 secretion.

Connolly JPR, Slater SL, O'Boyle N, Goldstone RJ, Crepin VF, Ruano-Gallego D, Herzyk P, Smith DGE, Douce GR, Frankel G, Roe AJ.

Nat Commun. 2018 Nov 29;9(1):5148. doi: 10.1038/s41467-018-07612-0.

4.

Host-associated niche metabolism controls enteric infection through fine-tuning the regulation of type 3 secretion.

Connolly JPR, Slater SL, O'Boyle N, Goldstone RJ, Crepin VF, Ruano-Gallego D, Herzyk P, Smith DGE, Douce GR, Frankel G, Roe AJ.

Nat Commun. 2018 Oct 10;9(1):4187. doi: 10.1038/s41467-018-06701-4. Erratum in: Nat Commun. 2018 Nov 29;9(1):5148.

5.

New class of precision antimicrobials redefines role of Clostridium difficile S-layer in virulence and viability.

Kirk JA, Gebhart D, Buckley AM, Lok S, Scholl D, Douce GR, Govoni GR, Fagan RP.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaah6813. doi: 10.1126/scitranslmed.aah6813.

6.

Analysis of Campylobacter jejuni infection in the gnotobiotic piglet and genome-wide identification of bacterial factors required for infection.

de Vries SP, Linn A, Macleod K, MacCallum A, Hardy SP, Douce G, Watson E, Dagleish MP, Thompson H, Stevenson A, Kennedy D, Baig A, Coward C, Maskell DJ, Smith DG, Grant AJ, Everest P.

Sci Rep. 2017 Mar 10;7:44283. doi: 10.1038/srep44283.

7.

Identification and Characterization of Novel Compounds Blocking Shiga Toxin Expression in Escherichia coli O157:H7.

Huerta-Uribe A, Marjenberg ZR, Yamaguchi N, Fitzgerald S, Connolly JP, Carpena N, Uvell H, Douce G, Elofsson M, Byron O, Marquez R, Gally DL, Roe AJ.

Front Microbiol. 2016 Nov 30;7:1930. eCollection 2016.

8.

Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.

McCaughey LC, Ritchie ND, Douce GR, Evans TJ, Walker D.

Sci Rep. 2016 Jul 22;6:30201. doi: 10.1038/srep30201.

9.

Lighting Up Clostridium Difficile: Reporting Gene Expression Using Fluorescent Lov Domains.

Buckley AM, Jukes C, Candlish D, Irvine JJ, Spencer J, Fagan RP, Roe AJ, Christie JM, Fairweather NF, Douce GR.

Sci Rep. 2016 Mar 21;6:23463. doi: 10.1038/srep23463.

10.

Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo.

Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MR.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):968-81. doi: 10.1128/AAC.01774-15. Print 2016 Feb.

11.

LOV-based reporters for fluorescence imaging.

Buckley AM, Petersen J, Roe AJ, Douce GR, Christie JM.

Curr Opin Chem Biol. 2015 Aug;27:39-45. doi: 10.1016/j.cbpa.2015.05.011. Epub 2015 Jun 15. Review.

12.

Signal regulatory protein alpha (SIRPα) regulates the homeostasis of CD103(+) CD11b(+) DCs in the intestinal lamina propria.

Scott CL, Tfp ZM, Beckham KS, Douce G, Mowat AM.

Eur J Immunol. 2014 Dec;44(12):3658-68. doi: 10.1002/eji.201444859. Epub 2014 Oct 27.

13.

The post-translational modification of the Clostridium difficile flagellin affects motility, cell surface properties and virulence.

Faulds-Pain A, Twine SM, Vinogradov E, Strong PC, Dell A, Buckley AM, Douce GR, Valiente E, Logan SM, Wren BW.

Mol Microbiol. 2014 Oct;94(2):272-89. doi: 10.1111/mmi.12755. Epub 2014 Sep 15.

14.

Cytological follow-up after hysterectomy: is vaginal vault cytology sampling a clinical governance problem? The University Hospital of North Staffordshire approach.

Parry-Smith W, Thorpe D, Ogboro-Okor L, Underwood M, Ismaili E, Kodampur M, Todd R, Douce G, Redman CW.

Cytopathology. 2015 Jun;26(3):188-93. doi: 10.1111/cyt.12178. Epub 2014 Aug 13.

PMID:
25123422
15.

The HtrA-like protease CD3284 modulates virulence of Clostridium difficile.

Bakker D, Buckley AM, de Jong A, van Winden VJ, Verhoeks JP, Kuipers OP, Douce GR, Kuijper EJ, Smits WK, Corver J.

Infect Immun. 2014 Oct;82(10):4222-32. doi: 10.1128/IAI.02336-14. Epub 2014 Jul 21.

16.

The metabolic enzyme AdhE controls the virulence of Escherichia coli O157:H7.

Beckham KS, Connolly JP, Ritchie JM, Wang D, Gawthorne JA, Tahoun A, Gally DL, Burgess K, Burchmore RJ, Smith BO, Beatson SA, Byron O, Wolfe AJ, Douce GR, Roe AJ.

Mol Microbiol. 2014 Jul;93(1):199-211. doi: 10.1111/mmi.12651. Epub 2014 Jun 9.

17.

Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models.

Spencer J, Leuzzi R, Buckley A, Irvine J, Candlish D, Scarselli M, Douce GR.

Gut Microbes. 2014 Mar-Apr;5(2):225-32. doi: 10.4161/gmic.27712. Epub 2014 Jan 22.

18.

Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, Veggi D, Pansegrau W, Fiaschi L, Savino S, Swennen E, Cakici O, Oviedo-Orta E, Giraldi M, Baudner B, D'Urzo N, Maione D, Soriani M, Rappuoli R, Pizza M, Douce GR, Scarselli M.

Infect Immun. 2013 Aug;81(8):2851-60. doi: 10.1128/IAI.01341-12. Epub 2013 May 28.

19.

Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.

Buckley AM, Spencer J, Maclellan LM, Candlish D, Irvine JJ, Douce GR.

PLoS One. 2013 May 21;8(5):e64121. doi: 10.1371/journal.pone.0064121. Print 2013.

20.

Emergence and global spread of epidemic healthcare-associated Clostridium difficile.

He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD.

Nat Genet. 2013 Jan;45(1):109-13. doi: 10.1038/ng.2478. Epub 2012 Dec 9.

21.

Is the colposcopically directed punch biopsy a reliable diagnostic test in women with minor cytological lesions?

Moss EL, Hadden P, Douce G, Jones PW, Arbyn M, Redman CW.

J Low Genit Tract Dis. 2012 Oct;16(4):421-6. doi: 10.1097/LGT.0b013e318250acf3.

PMID:
22669079
22.

Review of invasive cervical cancers and uptake of disclosure of results: an audit of procedures and response.

Prabakar I, Moss EL, Douce G, Parkes J, Redman CW.

Cytopathology. 2012 Jun;23(3):167-71. doi: 10.1111/j.1365-2303.2012.00974.x. Epub 2012 Apr 12. Review.

PMID:
22494343
23.

The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile.

Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, Spencer J, Buckley AM, Antunes A, Kotsanas D, Jenkin GA, Dupuy B, Rood JI, Lyras D.

PLoS Pathog. 2011 Oct;7(10):e1002317. doi: 10.1371/journal.ppat.1002317. Epub 2011 Oct 13.

24.

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291.

Buckley AM, Spencer J, Candlish D, Irvine JJ, Douce GR.

J Med Microbiol. 2011 Aug;60(Pt 8):1174-80. doi: 10.1099/jmm.0.028514-0. Epub 2011 Feb 17.

25.

Implementing the national invasive cervical cancer audit: a local perspective.

Moss EL, Pearmain P, Askew S, Owen G, Reynolds TM, Prabakar IM, Douce G, Parkes J, Menon V, Todd RW, Redman CW.

BJOG. 2010 Oct;117(11):1411-6. doi: 10.1111/j.1471-0528.2010.02679.x. Epub 2010 Aug 17.

26.

Refinement of the hamster model of Clostridium difficile disease.

Douce G, Goulding D.

Methods Mol Biol. 2010;646:215-27. doi: 10.1007/978-1-60327-365-7_14.

PMID:
20597012
27.

Cervical cytology/histology discrepancy: a 4-year review of patient outcome.

Moss EL, Moran A, Douce G, Parkes J, Todd RW, Redman CW.

Cytopathology. 2010 Dec;21(6):389-94. doi: 10.1111/j.1365-2303.2010.00754.x.

PMID:
20482721
28.

Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae.

Douce G, Ross K, Cowan G, Ma J, Mitchell TJ.

Vaccine. 2010 Apr 19;28(18):3231-7. doi: 10.1016/j.vaccine.2010.02.014. Epub 2010 Feb 24.

PMID:
20188176
29.

Synchrotron-based FTIR spectra of stained single cells. Towards a clinical application in pathology.

Pijanka J, Sockalingum GD, Kohler A, Yang Y, Draux F, Parkes G, Lam KP, Collins D, Dumas P, Sandt C, van Pittius DG, Douce G, Manfait M, Untereiner V, Sulé-Suso J.

Lab Invest. 2010 May;90(5):797-807. doi: 10.1038/labinvest.2010.8. Epub 2010 Feb 1.

30.

Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1.

Goulding D, Thompson H, Emerson J, Fairweather NF, Dougan G, Douce GR.

Infect Immun. 2009 Dec;77(12):5478-85. doi: 10.1128/IAI.00551-09. Epub 2009 Sep 14.

31.

Multidisciplinary colposcopy clinicopathology correlation meetings: an activity review.

Moss EL, Byrom J, Owen G, Pearmain P, Douce G, Todd R, Redman CW.

J Low Genit Tract Dis. 2009 Jul;13(3):169-73. doi: 10.1097/LGT.0b013e3181914344.

PMID:
19550215
32.

Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.

Orr B, Douce G, Baillie S, Parton R, Coote J.

Vaccine. 2007 Jan 2;25(1):64-71. Epub 2006 Jul 31.

PMID:
16916566
33.

A proteomic analysis of arsenical drug resistance in Trypanosoma brucei.

Foucher AL, McIntosh A, Douce G, Wastling J, Tait A, Turner CM.

Proteomics. 2006 May;6(9):2726-32.

PMID:
16526094
34.

Should punch biopsies be used when high-grade disease is suspected at initial colposcopic assessment? A prospective study.

Byrom J, Douce G, Jones PW, Tucker H, Millinship J, Dhar K, Redman CW.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):253-6.

PMID:
16445640
35.

Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Kirkham LA, Kerr AR, Douce GR, Paterson GK, Dilts DA, Liu DF, Mitchell TJ.

Infect Immun. 2006 Jan;74(1):586-93.

36.

A vaccination strategy incorporating DNA priming and mucosal boosting using tetanus toxin fragment C (TetC).

Stratford R, Douce G, Bowe F, Dougan G.

Vaccine. 2001 Nov 12;20(3-4):516-25.

PMID:
11672917
37.

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G.

Vaccine. 2001 Mar 21;19(17-19):2534-41. Review.

PMID:
11257389
38.

Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus.

Stratford R, Douce G, Zhang-Barber L, Fairweather N, Eskola J, Dougan G.

Vaccine. 2000 Nov 22;19(7-8):810-5.

PMID:
11115703
39.

LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.

Pizza M, Giuliani MM, Fontana MR, Douce G, Dougan G, Rappuoli R.

Int J Med Microbiol. 2000 Oct;290(4-5):455-61. Review. No abstract available.

PMID:
11111926
40.

Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery.

Falero-Diaz G, Challacombe S, Rahman D, Mistry M, Douce G, Dougan G, Acosta A, Ivanyi J.

Int Arch Allergy Immunol. 2000 Jun;122(2):143-50.

PMID:
10878493
41.

The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.

Dougan G, Ghaem-Maghami M, Pickard D, Frankel G, Douce G, Clare S, Dunstan S, Simmons C.

Philos Trans R Soc Lond B Biol Sci. 2000 May 29;355(1397):705-12. Review.

42.

Intranasal vaccination of mice against infection with Mycobacterium tuberculosis.

Falero-Diaz G, Challacombe S, Banerjee D, Douce G, Boyd A, Ivanyi J.

Vaccine. 2000 Aug 1;18(28):3223-9.

PMID:
10869767
43.

Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines.

Sydenham M, Douce G, Bowe F, Ahmed S, Chatfield S, Dougan G.

Infect Immun. 2000 Mar;68(3):1109-15.

44.

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.

Rappuoli R, Pizza M, Douce G, Dougan G.

Immunol Today. 1999 Nov;20(11):493-500. Review. No abstract available.

PMID:
10529776
46.
47.

Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Douce G, Giannelli V, Pizza M, Lewis D, Everest P, Rappuoli R, Dougan G.

Infect Immun. 1999 Sep;67(9):4400-6.

48.
49.

Evaluation of Salmonella typhimurium mutants in a model of experimental gastroenteritis.

Everest P, Ketley J, Hardy S, Douce G, Khan S, Shea J, Holden D, Maskell D, Dougan G.

Infect Immun. 1999 Jun;67(6):2815-21.

50.

Supplemental Content

Support Center